10 years ago

Centauri Therapeutics Secures £3 Million to Combat Anti-Microbial Resistance

  • Centauri Therapeutics, a UK-based biotechnology company focused on treating infectious diseases, has raised £3 million in funding

  • The funding will be used to develop the company's first lead Alphamers against anti-microbial resistant pathogens

  • The company acquired the Alphamer technology from Altermune Technologies LLC and appointed Dr Clive Dix as Chairman.

      • ProblemHealthcare

      "Centauri Therapeutics is addressing the issue of anti-microbial resistant pathogens, which pose a significant challenge in the treatment of infectious diseases."

      Solution

      "The company is developing Alphamers, a novel drug discovery and development technology, to combat anti-microbial resistant pathogens."

      Covered on